Chongqing Genrix Biopharmaceutical Co., Ltd. Class A
SSSE:68844324.11
CNY
+1.23
(+5.38%)
ISIN
CNE100006KG8
Return %
Stock
S&P 500
1Y
-14.93
14.20
3Y
-17.54
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhi Gang Liu
- Full Time Employees
- 984
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Chongqing China
- IPO Date
- Jun 20, 2023
- Website
- genrixbio.com
- Similar Companies
- Business
- Chongqing Genrix Biopharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company that specializes in the discovery, research, development, clinical evaluation, and manufacturing of innovative therapeutic antibody drugs targeting autoimmune disorders, infectious diseases, and malignant tumors. Founded in 2015 and headquartered in Chongqing, China, the company operates an integrated proprietary biologics platform that encompasses target discovery, high-throughput antibody screening, protein engineering, cell line construction, bioprocess optimization, quality management, and cGMP-compliant commercial manufacturing. The company's product portfolio and clinical pipeline comprise proprietary monoclonal, bispecific, and polyspecific antibodies, including: Jinlixi (xeligekimab / GR1501), an approved recombinant fully human anti-interleukin-17A (IL-17A) monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis and ankylosing spondylitis; velinotamig (GR1803), a recombinant humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 for the treatment of adult patients with relapsed or refractory multiple myeloma; telikibart (GR1802), a recombinant humanized anti-interleukin-4 receptor alpha (IL-4Rα) monoclonal antibody in advanced Phase III clinical development for moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and seasonal allergic rhinitis; silevimig (GR1801), an anti-rabies virus glycoprotein recombinant bispecific antibody engineered for post-exposure prophylaxis of rabies; vecantoxatug (GR2001), an anti-tetanus toxin monoclonal antibody for passive immunization against tetanus infection; GR2002, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) for severe asthma; GR2102, an anti-respiratory syncytial virus (RSV) monoclonal antibody; GR2301, an anti-interleukin-15 (IL-15) monoclonal antibody; and GR2302, a therapeutic monoclonal antibody in clinical investigation for chronic hepatitis B. In recent corporate developments, Chongqing Genrix Biopharmaceutical Co., Ltd. secured National Medical Products Administration (NMPA) approval for velinotamig (GR1803) under priority review for multiple myeloma; entered into an exclusive commercialization and clinical development licensing agreement for GR1803 across Greater China with Chongqing Yaopharma, a subsidiary of Shanghai Fosun Pharmaceutical, featuring upfront and milestone considerations totaling up to 1.82 billion yuan along with tiered sales royalties; established a strategic commercial distribution and hospital channel partnership with China Resources Medicine Commercial Group; received expanded NMPA indication approval for xeligekimab (GR1501) for ankylosing spondylitis following its initial commercial launch for plaque psoriasis; and advanced multiple innovative biologic candidates into clinical-stage trials.